World Malaria Day: protect communities from relapsing P. vivax malaria
This World Malaria Day, let's support Malaria research
This World Malaria Day, let's support evidence for relapsing malaria.
This World Malaria Day, Zero Malaria Starts with Me
Plasmodium vivax infection is present across most of the malaria-endemic world. P. vivax relapses, arising from dormant liver stages, cause recurrent episodes of malaria that are the main determinant of significant morbidity, mortality, and ongoing transmission.
This tool assesses the cost-effectiveness of using G6PD RDTs prior to the administration of primaquine.
The vivax after falciparum Study Group was formed in March 2018, with an invitation to interested researchers with relevant data sets.
Efforts to eradicate Plasmodium vivax malaria are hampered by the presence of hypnozoites, persisting stages in the liver that can reactivate after prolonged periods of time enabling further transmission and causing renewed disease. Large-scale drug screening is needed to identify compounds with antihypnozoite activity, but current platforms rely on time-consuming high-content fluorescence imaging as read-out, limiting assay throughput.
During April-June 2014 in a malaria-endemic rural community close to the city of Iquitos in Peru, we detected evidence of Guaroa virus (GROV) infection in 14 febrile persons, of whom 6 also had evidence of Plasmodium vivax malaria.
This recent event of large-scale re-introduction of vivax malaria in a temperate area, Russia, can serve as a case study for further research.